The notion that colorectal PC is a locoregional disease has led to the development of a novel strategy combining complete cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), which has yielded encouraging results and led to the successful management of peritoneal surface malignancy. In 1980, Spratt was the first to describe the combination of maximal CRS with HIPEC to treat a recurring peritoneal pseudomyxoma, but this method was further introduced and established by Paul Sugarbaker